| Sorbent raises $36M for heart failure drug - Bizjournals.com |
|
|
Bizjournals.com The Sunnyvale biopharm, which focuses on therapies for cardiovascular and renal disorders, said the latest round brings total funding to $53 million so far. New investor Novartis Venture Funds, an arm of Switzerland-based Novartis, led the round. ... Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 |